Help protect patients 2 months through 55 years old against MenACWY with MENVEO—a trusted* meningitis vaccine1,2

Vaccination may not protect all recipients.
Not actual patients.

MENVEO is approved in 2 presentations1

  • MENVEO 1-vial presentation is approved for use in individuals aged 10 through 55 years

  • MENVEO 2-vial presentation is approved for use in individuals aged 2 months through 55 years

Your patients need a primary dose of MenACWY vaccine at age 11-12, and a booster dose at 16-18 years of age to complete MenACWY vaccination according to AAP and CDC recommendations.3,4
Clipboard icon

Be sure to check your records

According to 2024 CDC data, 92% of 17-year-olds had received a primary dose of a MenACWY vaccine — but only 61% had received ≥ 2 doses.5 Are you doing all you can to help protect your patients?

SEE RECOMMENDATIONS

FDA-approved MENVEO dosing for adolescents and adults

Primary Vaccination

SINGLE DOSE in adolescents and adults aged 10 through 55 years1

Booster Vaccination

SINGLE DOSE in individuals 15 through 55 years of age who are at continued risk of meningococcal disease, at least 4 years after a prior dose of a MenACWY vaccine1

*Based on a survey of 100 physicians in 2024 in which physicians reported trusting MENVEO and other meningococcal vaccines to vaccinate their patients.2

AAP=American Academy of Pediatrics; CDC=Centers for Disease Control and Prevention; FDA=Food and Drug Administration; MenACWY=meningococcal serogroups A, C, W, Y.

Shopping cart icon

Order MENVEO

Visit the GSK portal or contact your wholesaler/distributor to place an order today.

GO TO GSKDIRECT.COM
Important information icon

Learn more

about meningococcal disease and what you can do to help prevent it.

FIND OUT MORE
Shield with syringe icon

See the data

on immunogenicity after a booster dose of MENVEO.

EXPLORE MORE
Scroll with quill pen icon

Learn more

about the GSK Meningococcal Vaccines Portfolio.

EXPLORE THE PORTFOLIO

Indication & Important Safety Info

Indication

Important Safety Information for MENVEO

Indication

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

Important Safety Information for MENVEO

  • Do not administer MENVEO to individuals with a severe allergic reaction (eg, anaphylaxis) to a previous dose of MENVEO, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
  • Appropriate medical treatment must be available should an acute allergic reaction, including an anaphylactic reaction, occur following administration of MENVEO
  • Syncope (fainting) has occurred in association with administration of MENVEO. Procedures should be in place to avoid injury from fainting
  • Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to MENVEO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W, even if they develop antibodies following vaccination with MENVEO
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of another US-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision to administer MENVEO to individuals with a history of GBS should take into account the expected benefits and potential risks
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. A decision about when to administer MENVEO to an infant born prematurely should be based on consideration of the individual infant’s medical status and the potential benefits and possible risks of vaccination
  • Common solicited adverse reactions with MENVEO among children initiating vaccination: at 2 months of age and receiving the four-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, vomiting, and diarrhea; at 7 months through 23 months of age and receiving the two-dose series were tenderness and erythema at injection site, irritability, sleepiness, persistent crying, change in eating habits, and diarrhea; at 2 through 10 years of age who received MENVEO were injection site pain, erythema, irritability, induration, sleepiness, malaise, and headache. Common solicited adverse reactions among adolescents and adults aged 11 through 55 years who received a single dose of MENVEO were pain at the injection site, headache, myalgia, malaise, and nausea. Across all age groups, some events were severe. Similar rates of solicited adverse reactions among adolescents and adults were observed following a single booster dose
  • In two clinical studies, there were no notable differences in frequency and severity of solicited adverse reactions in individuals who received MENVEO 1-vial presentation compared to individuals who received the 2-vial presentation
  • Vaccination with MENVEO may not result in protection in all vaccine recipients

 

Please see full Prescribing Information for MENVEO.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at gsk.public.reportum.com or
1-888-825-5249, or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

References

  1. Prescribing Information for MENVEO.

  2. Data on file. 2024N560264_00. GSK.

  3. Recommended child and adolescent immunization schedule for ages 18 years or younger. United States 2026. American Academy of Pediatrics. Updated February 5, 2026. Accessed March 3, 2026. https://downloads.aap.org/AAP/PDF/AAP-Immunization-Schedule.pdf

  4. Amin AB, Collins JP, Dong X, et al. Use of the GSK MenACWY-CRM/MenB-4C pentavalent meningococcal vaccine among persons aged ≥10 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2025. MMWR. 2026;75(1):7-14. doi:10.15585/mmwr.mm7501a2

  5. Pingali C, Yankey D, Elam-Evans LD, et al. National vaccination coverage among adolescents aged 13-17 years — National Immunization Survey-Teen, United States, 2024. MMWR. 2025;74(30):466-472. doi:10.15585/mmwr.mm7430a1